Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 10/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.41 |
| ▸ | HRH2 | P25021 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Impentamine SCHEMBL7860359 | 0.98 | HRH1 (0.47) | HRH1HRH3HRH4HRH2 | |
| Homohistamine SCHEMBL1073990 | 0.94 | — | — | |
| Histamine SCHEMBL9683835 | 0.92 | HRH3 (0.38) | HRH1HRH3HRH4HRH2 | |
| Homohistamine SCHEMBL18984998 | 0.92 | HRH3 (0.38) | HRH1HRH3HRH4HRH2PDPK1 | |
| Homohistamine SCHEMBL7971411 | 0.92 | HRH3 (0.38) | HRH1HRH3HRH4HRH2PDPK1 | |
| Histamine SCHEMBL1668636 | 0.85 | HRH4 (0.42) | HRH1HRH3HRH4HRH2 | |
| Histamine SCHEMBL5447892 | 0.85 | — | — | |
| Histamine SCHEMBL27340939 | 0.85 | — | — | |
| Histamine SCHEMBL7444650 | 0.85 | HRH4 (0.42) | HRH1HRH3HRH4HRH2 | |
| Histamine SCHEMBL289072 | 0.85 | HRH4 (0.42) | HRH1HRH3HRH4HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111836899-B | Method for producing an intermediate for the synthesis of optically active beta-amino alcohols by enzymatic reduction and synthetic intermediate | 欧伦股份公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11564970-B2 | Compositions and methods for combinatorial drug discovery in nanoliter droplets | THE BROAD INSTITUTE, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11383084-B2 | Treatment of dermatological conditions via neuromodulation | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210371548-A1 | HYALURONIC ACID DERIVATIVE MODIFIED WITH POLYETHYLENE GLYCOL | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-12-02 | — | — | US | disclosed |
| EP-3712181-A1 | HYALURONIC ACID DERIVATIVE MODIFIED WITH POLY(ETHYLENE GLYCOL) | Chugai Seiyaku Kabushiki Kaisha (JP) | 2020-09-23 | — | — | EP | disclosed |
| US-20190142959-A1 | HYALURONIC ACID DERIVATIVES INTO WHICH CATIONIC AND HYDROPHOBIC GROUPS ARE INTRODUCED | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-05-16 | — | — | US | disclosed |
| EP-3456745-A1 | HYALURONIC ACID DERIVATIVE HAVING CATIONIC GROUP AND HYDROPHOBIC GROUP INTRODUCED THEREIN | Chugai Seiyaku Kabushiki Kaisha (JP) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017195880-A1 | HYALURONIC ACID DERIVATIVE HAVING CATIONIC GROUP AND HYDROPHOBIC GROUP INTRODUCED THEREIN | 中外製薬株式会社 | 2017-11-16 | — | — | WO | disclosed |
| EP-1497309-B1 | AMINOALKYL STEROL COMPOUNDS HAVING AN ANTI-TUMORAL AND NEUROPROTECTIVE ACTIVITY | INST NAT SANTE RECH MED (FR) | 2009-01-14 | — | — | EP | disclosed |
| EP-1318983-B1 | SUBSTITUTED IMIDAZOLES AS HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| US-4120968-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-10-17 | — | — | US | disclosed |
| US-4118502-A | ANTIHISTAMINE | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-10-03 | — | — | US | disclosed |
| US-RE29761-E | INHIBITORS OF H-2 HISTAMINE RECEPTORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-09-12 | — | — | US | disclosed |
| US-4112104-A | UREA, THIOUREA OR GUANIDINE DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-09-05 | — | — | US | disclosed |
| US-4105770-A | HISTAMINE ANTIAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-08-08 | — | — | US | disclosed |
| US-4098898-A | N-SUBSTITUTED-N'-HETEROCYCLIC ALKYLTHIOUREAS, GUANIDINES, AND ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-07-04 | — | — | US | disclosed |
| US-4080459-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1978-03-21 | — | — | US | disclosed |
| US-4025527-A | H-2 HISTAMINE RECEPTOR INHIBITORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-24 | — | — | US | disclosed |
| US-4024260-A | INHIBITS H-2 HISTAMINE RECEPTORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-17 | — | — | US | disclosed |
| US-4013769-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371548-A1 | HYALURONIC ACID DERIVATIVE MODIFIED WITH POLYETHYLENE GLYCOL | CD44, F12, HPSE | HRH1 97/4885HRH3 153/4885HRH4 397/4885 |
| US-11564970-B2 | Compositions and methods for combinatorial drug discovery in nanoliter droplets | RAB5IF, LIPA, CLTB | HRH1 2869/4885HRH3 3166/4885HRH4 3614/4885 |
| US-20190142959-A1 | HYALURONIC ACID DERIVATIVES INTO WHICH CATIONIC AND HYDROPHOBIC GROUPS ARE INTRODUCED | CD44, MUC1, FUT5 | HRH1 63/4885HRH3 61/4885HRH4 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.